36 results about "Eating disorders" patented technology

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

Disclosed herein is a method for treating, preventing, and / or slowing the progression of various chronic inflammatory condition groups including: (1) the Type 2 Diabetes group (Metabolic Syndrome (MET), obesity, hyperglycemia); (2) ARDS (Acute Respiratory Distress Syndrome); (3) chronic autoimmune inflammatory conditions (Rheumatoid Arthritis (RA), Lupus, and Psoriasis); (4) inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; (5) metabolite group-mediated diseases (atherosclerosis, hypertension, and congestive heart failure); and (6) eating disorders, such as Prader-Willi Syndrome and other monogenic and symptomatic obesity disorders including leptin pathway defects, each method comprising orally administering a pharmaceutical composition comprising a denatonium salt. The present disclosure is based on the results of a series of studies that tracked biomarker cluster levels to track mediators of inflammatory conditions and mediators of gut signaling hormones in response to orally administered denatonium salts.

Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions, such as in the methods for safely treating chemical dependency on a substance or condition of addiction, such as alcohol, nicotine, cocaine, opiates, amphetamines, and compulsive eating disorder, and / or anxiety disorder, each individually or concurrent.

To provide Akt3 modulators and compounds and pharmaceutical compositions for treating diseases by modulation of Akt3 signaling.SOLUTION: A compound of Formula Ib or Ic, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound for treating a disease in a subject in need thereof, A pharmaceutical composition wherein the treatment comprises administering to a subject an effective amount of the compound; optionally wherein the disease is selected from the group consisting of neurodegenerative diseases, cachexia, eating disorders, obesity, complications of obesity, inflammatory diseases, virally-induced inflammatory reactions, Gulf War Syndrome, tuberous sclerosis, retinitis pigmentosa, graft rejection, cancer, autoimmune diseases, ischemic tissue injury, traumatic tissue injury and combinations thereof.SELECTED DRAWING: Figure 6

Methods of treating one or more eating disorders including anorexia nervosa, bulimia, and related clinical syndromes in a subject in need thereof are described. In some cases, electric stimulation and / or one or more active agents are administered to a subject in need thereof to reduce or inhibit the activity of CeA PKC-δ neurons and ovBNST PKC-δ neurons in the brain of the subject. Preferably, the disclosed methods are effective to increase or excite the activity of the brain regions downstream of CeA PKC-δ neurons and ovBNST PKC-δ neurons including medial part of CeA and ventral lateral part of BNST.

Methods and systems are provided for taking physiological marker measurements for a patient suffering from an eating disorder (e.g., anorexia nervosa, greedy nervosa, violent eating, heterophagia syndrome, ruminant disorder, or truncated food intake). Mathematical analysis of physiological marker measurements is used to create a unique personal prediction model and a unique personal data set for an individual patient, including personal prediction of the entire stage of a disorder (violence, nausea and clearance). The unique personal data set is used to diagnose and monitor specific issues of individual patients associated with eating disorders, determine the severity of the disorders, provide intraday alarms to assist in sustained disorder management or recommend treatment of specific issues of individual patients associated with these eating disorders, or predicts the outcome of a treatment for a particular problem of individual patients associated with these eating disorders.

The present invention relates to the field of pharmacy, and in particular to compounds of formula (I) as pharmaceutically active compounds. Compounds of formula (I) have been proven for the first time to be particularly useful for the treatment of depression and eating disorders related to depression, or diseases with depressive pathology as well as for the treatment of appetite related side effects of antidepressants and antipsychotics.

Methods of treating a subject having a metabolic syndrome or disease, diabetes, obesity, overweight, eating disorders, polyphagia, hyperlipidemia, insulin resistance, or methods of reducing body weight in a subject are provided. The methods involve administering to the subject a composition comprising a compound of formula I, including, for example, GAL475 (l-(2, 6-dimethylamino-8-propylamino-pyrimido [5, 4-d] pyrimidin-4-ylamino)-2-methyl-propan-2-ol), e.g., GAL475 (l-(2, 6-dimethylamino-8-propylamino-pyrimido [5, 4-d] pyrimidin-4-ylamino)-2-methyl-propan-2-ol), e.g., GAL475 (l-(2, 6- or a pharmaceutically acceptable salt, solvate, hydrate, enantiomer, stereoisomer, tautomer or isotope variant thereof, and a pharmaceutically acceptable carrier or excipient.

The present disclosure provides a compound of formula (I): JPEG2026506861000048.jpg37170, or a pharmaceutically acceptable salt and / or solvate thereof. The present disclosure also relates to the use of the compounds of formula (I) as pharmaceuticals, in particular for the prevention or treatment of addictions, obsessive-compulsive disorders and related behaviors, including obsessive-compulsive disorders and eating disorders, and neurodegenerative disorders such as Parkinson's disease or Alzheimer's disease.

This disclosure describes methods of increasing or decreasing food intake, including regulation of glucagon-like peptide 1 (GLP-1) pathways. Also disclosed are methods of increasing or decreasing food intake, preventing food aversion reactions, and treating various diseases and disorders including obesity and eating disorders. Also described herein are methods of evaluating C. elegans to identify means to regulate food intake.

This invention relates to the use of mGluR5 positive allosteric modulators in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, post-traumatic stress disorder, substance use disorder, depression-related aspects of schizophrenia (e.g. negative symptoms and cognitive impairment associated with schizophrenia), obsessive compulsive disorder, an eating disorder, autism spectrum disorder, chemotherapy-related cognitive dysfunction, Parkinson's disease, multiple sclerosis, clinical high risk for psychosis, and attenuated psychosis syndrome in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

The invention concerns methods for treating unwanted body weight loss, and / or medically undesired body weight loss, or eating disorders (such as anorexia nervosa), by administration of a leptin receptor agonist, such as metreleptin. The invention also relates to methods for increasing body weight in a subject in need of the treatment.

A hybrid bioelectronic implantable device containing engineered cells for delivery of therapeutic agents to a subject to treat a medical condition of the subject. The device comprises an implantable device implantable inside the subject's body, wherein the implantable device comprises at least one cell housing containing the engineered cells; and an optical stimulating system within the at least one cell housing, wherein the optical stimulating system is configured to control production of at least one type of therapeutic agents by the engineered cells; wherein the medical condition of the subject comprises one of a sleep disorder, a circadian rhythm disorder, neuro disorders, infertilities, diabetes, obesity, eating disorders, cancers, bone marrow disorders, autoimmune disorders, addictive disorders.

The present disclosure relates generally to methods of treating various diseases, conditions, and conditions, such as depressive disorder (e.g., major depressive disorder (MDD)), substance use disorder, anxiety disorder, eating disorder, pain, and headache disorder, by administering deuterated gymnosin and pharmaceutically acceptable salts, polymorphs, or solvates thereof.

A fused ring compound of formula I, a pharmaceutical composition comprising same, a preparation method, a use for preventing and treating GPR6 receptor-mediated related diseases, such as movement disorders including Parkinson's disease, levodopa-induced dyskinesias, and Huntington's disease, drug addiction, eating disorders, cognitive disorders, schizophrenia, bipolar disorder, depression, etc., and a method.

The present application relates to the technical field of bioengineering, and particularly relates to a neurotensin cyclic peptide and a preparation method and application thereof.The present application comprises the following steps: preparing a peptide chain; then washing the peptide chain, adding a mixed solution of trifluoroethanol and dichloromethane, oscillating, and filtering to obtain a linear peptide crude product; adding a dichloromethane solution containing hydroxybenzotriazole, benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate and diisopropylethylamine to the linear peptide crude product, performing a cyclization reaction, reducing pressure concentration and purification to obtain a cyclization peptide crude product; after C-terminal amidation and side chain deprotection of the cyclization peptide crude product, separating and purifying to obtain the neurotensin cyclic peptide. By constructing a more stable and more active NST cyclic peptide, not only the convenience of subsequent NST related research is improved, but also the present application can serve as a research basis for developing a new potential drug for treating obesity and eating disorders (such as binge eating disorder).

A gastrointestinal implant adapted to be implanted in a gastrointestinal structure such as a duodenum, a jejunum, and / or an ileum comprises a plurality of adjacent layers bonded to one another. One of more of the layers comprises at least one of a selected pore size and interpore distance, and at least one medicament is coupled to at least one medial surface of one or more layers to achieve one or more treatment goals selected from minimizing or alleviating trauma associated with implantation of the gastrointestinal sleeve, preventing or treating infection, treating eating disorders or conditions of the patient, treating one or more gastrointestinal tract structures exterior to or distal to at least a portion of the sleeve, or treating the patient's microbiome.

The present disclosure relates to compositions and methods of treating psychological conditions, such as eating disorders, using pharmaceutical compositions comprising 3- Methylmethcathinone (3-MMC), or a pharmaceutically acceptable salt thereof.

Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions, such as in the methods for safely treating chemical dependency on a substance or condition of addiction, such as alcohol, nicotine, cocaine, opiates, amphetamines, and compulsive eating disorder, and / or anxiety disorder, each individually or concurrent.

The present disclosure relates to compositions comprising 3, 4-methylenedioxy methyl amphetamine (MDMA), or a salt thereof, and MDMA, or a pharmaceutically acceptable salt thereof, in combination with N-acylethanolamine, or a pharmaceutically acceptable salt thereof (e.g., a pharmaceutically acceptable salt thereof). The present invention relates to pharmaceutical compositions comprising a combination of N, N '-dihydroxybutyramide ("PEA") and at least one pharmaceutically acceptable carrier and / or excipient and their use in methods of treating post-traumatic stress disorder (PTSD), anxiety and eating disorders by administering the composition in a therapeutically effective amount to a subject in need thereof.

The present invention relates to a composition comprising a probiotic composition comprising a Lactobacillus salivarius strain and a Lactobacillus gasseri strain. The invention further relates to the nutraceutical and therapeutical uses of such compositions in oxytocin-related neuropsychiatric disorders, in particular autism or anxiety related disorders selected from depression and eating disorders.

An orally disintegrating pharmaceutical tablet comprising: between 0.1 and 21 wt % of cariprazine or its pharmaceutically acceptable salts, between 0.1 and 15 wt % of a disintegrant, between 0.1 and 5 wt % of colloidal silicon dioxide, between 0.1 and 10 wt % of a taste masking agent, between 0.1 and 5 wt % of a lubricant, and up to 100 wt % of a diluent, the percentage being expressed with regard to the total weight of the pharmaceutical tablet. Said composition for use in the treatment and / or prevention of pathological conditions which require the modulation of dopamine receptors, selected from the group of psychoses, drug abuse, cognitive impairment accompanying schizophrenia, mild-to-moderate cognitive deficits, dementia, psychotic states associated with dementia, eating disorders, attention deficit disorders, hyperactivity disorders in children, psychotic depression, bipolar disorder, paranoid and delusional disorders, dyskinetic disorders, anxiety, sexual dysfunction, sleep disorders, emesis, aggression and autism.

The application relates to an eating disorder intervention method and system based on a structured multi-module course, the method comprising: a user terminal sending a course access request to a server; the server obtaining a user course progress according to the course access request, determining a target course unit matched with the user course progress according to a course arrangement rule, searching for course unit data of the target course unit from a structured course database, and sending the course unit data to the user terminal; the user terminal presenting the course unit data of the target course unit to the user, guiding the user to perform an intervention task through an interactive interface, collecting corresponding structured user state data, and sending the collected user state data to the server; and the server judging whether a specified task of the target course unit is completed according to the user state data, updating the user course progress if the specified task is completed, and not updating the user course progress if the specified task is not completed. The application realizes forced guidance, standardized implementation and automatic management of a structured treatment process.

The present invention relates to a novel daily low dosage regimen of donepezil and its derivatives or pharmaceutically acceptable salts and / or solvates for use in the prevention and / or treatment of obsessive-compulsive disorders, in particular eating disorders. The invention also relates to a unit dosage form comprising from 0.25 mg to 2.5 mg of donepezil, derivatives or pharmaceutically acceptable salts and / or solvates thereof, in particular for use in the prevention and / or treatment of obsessive-compulsive disorders, in particular eating disorders.

The present invention relates to new uses of a 5-HT4 receptor agonist, specifically Isopropyl-3 - { 5- [ 1 -(3 - methoxypropyl) piperidin-4-yl] - [ 1,3,4] oxadiazol-2-yl } - 1 H- indazole (Compound- 1) or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, cognitive deficits associated with schizophrenia, depression, chemotherapy-induced cognitive impairment and behavioural and psychological symptoms of dementia such as apathy / indifference, agitation, aggression, depression, anxiety, irritability / lability, dysphoria, aberrant motor behaviour, delusions, hallucinations, elation / euphoria, psychosis, disinhibition, sleep and night time behaviour disorders or appetite and eating disorders. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.